NCT02181998已完成3 期
A Phase IIIb-IV, Randomised, Open Label Trial on Efficacy and Safety of 2 Parallel Groups: Full Dose Tenecteplase Combined With Unfractionated Heparin or Enoxaparin in Acute Myocardial Infarction in the Prehospital Setting (ASSENT 3 Plus) ASSENT 3 Plus Was a Satellite Study to ASSENT 3 (Main Study) ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,606
- 主要终点
- Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia
研究概览
简要总结
The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with enoxaparin (ENOX, group B). An additional objective in ASSENT 3 Plus was to describe the different time intervals in the prehospital phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Onset of symptoms of AMI within six hours prior to randomisation
- •A 12-lead ECG with one of the following: ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or left bundle-branch block
- •Informed consent received
排除标准
- •Hypertension defined as blood pressure (BP) > 180/110 mmHg (systolic blood pressure (SBP) 180 mmHg and/or diastolic blood pressure (DBP) > 110 mmHg) on repeated measurements during current admission prior to randomisation
- •Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the preceding seven days
- •Major surgery, biopsy of a parenchymal organ, or significant trauma within two months
- •Any minor head trauma and any other trauma occurring after onset of the current myocardial infarction (MI)
- •Any known history of stroke or transient ischaemic attack or dementia
- •Any known structural damage of the central nervous system
- •Prolonged cardiopulmonary resuscitation (> 10 min) in the previous two weeks
- •Current oral anticoagulation
- •Standard UFH (heparin sodium) > 5000 international units (IU), or a subcutaneous (SC) therapeutic dose of any low molecular weight heparin (LMWH) within six hours of randomisation
- •Known thrombocytopenia (prior platelet count below 100 000 cells/μL (100 x 10**9/L))
- •Known renal insufficiency (prior S-creatinine > 2.5 mg % (> 220 μmol/L) for men and 2.0 mg % (> 175 μmol/L)) for women
- •Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential had to have a negative pregnancy test, or use a medically accepted method of birth control
- •Treatment with an investigational drug under another study protocol in the past seven days
- •Previous enrolment in this study
- •Known sensitivity to tenecteplase, tissue plasminogen activator (tPA), abciximab, heparin or LMWH
- •Any other condition that the investigator felt would place the patient at increased risk if the investigational therapy was initiated (e.g. known haemorrhagic diathesis, acute pericarditis and/or subacute bacterial endocarditis, acute pancreatitis, severe hepatic dysfunction, diabetic haemorrhagic retinopathy or other haemorrhagic ophthalmic conditions, active peptic ulceration, arterial aneurysm and known arterial/venous malformation, neoplasm with increased bleeding risk)
- •Inability to follow protocol and comply with follow-up requirements
研究组 & 干预措施
tenecteplase + unfractioned heparin
Active Comparator
干预措施: Full dose tenecteplase (Drug)
tenecteplase + unfractioned heparin
Active Comparator
干预措施: Unfractioned heparin (Drug)
tenecteplase + enoxaparin
Experimental
干预措施: Full dose tenecteplase (Drug)
tenecteplase + enoxaparin
Experimental
干预措施: Enoxaparin (Drug)
结局指标
主要结局
Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia
时间窗: Up to 30 days after discharge from hospital
Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH)
时间窗: Up to 30 days after discharge from hospital
次要结局
未报告次要终点
研究者
相似试验
Unknown
3 期
European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsAlzheimer's DiseaseNCT00217763Bellus Health Inc. - a GSK company930
已完成
3 期
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)Myocardial InfarctionNCT02181985Boehringer Ingelheim5,989
已完成
3 期
Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic DiseasesInfluenza DiseaseNCT00519064Novartis Vaccines361
已完成
3 期
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined TherapyChronic Hepatitis CNCT00086541Bausch Health Americas, Inc.515
已完成
3 期
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined TherapyChronic Hepatitis CNCT00162734Bausch Health Americas, Inc.144